cardiovascularКардиоваскулярная терапия и профилактикаCardiovascular Therapy and Prevention1728-88002619-0125«SILICEA-POLIGRAF» LLC10.15829/1728-8800-2021-2974cardiovascular-2974Research ArticleКЛИНИКА И ФАРМАКОТЕРАПИЯCLINIC AND PHARMACOTHERAPYАнтикоагулянтная терапия при катетерной аблации фибрилляции и трепетания предсердийAnticoagulant therapy in catheter ablation of atrial fibrillation and flutterhttps://orcid.org/0000-0003-0608-9205СероваМ. В.SerovaM. V.

Серова Мария Владимировна — кандидат медицинских наук, ассистент кафедры кардиологии, функциональной и ультразвуковой диагностики ИКМ им. Н.В. Склифосовского, врач кардиолог отделения хирургического лечения сложных нарушений ритма сердца и электрокардиостимуляции.

Москва.

Тел.: +7 (926) 043-46-06

Maria V. Serova - Assistant Professor of the department of cardiology, functional and ultrasound diagnostics N.V. Sklifosovsky Clinical  Medicine Institution.

Moscow.

Tel.: +7 (926) 043-46-06

yamarfa@yandex.ruhttps://orcid.org/0000-0002-0276-7374АндреевД. А.AndreevD. A.

Андреев Денис Анатольевич — доктор медицинских наук, профессор, заведующий кафедрой кардиологии, функциональной и ультразвуковой диагностики ИКМ им. Н.В. Склифосовского, директор клиники кардиологии УКБ № 1.

Москва.

Denis A. Andreev - Professor, Head of the department  of cardiology, functional and ultrasound diagnostics N.V. Sklifosovsky Clinical  Medicine Institution; Director of the Clinic of cardiology UKB № 1 of the I.M. Sechenov First Moscow State Medical University (Sechenov University).

Moscow.

dennan@mail.ruhttps://orcid.org/0000-0002-9593-6148ЧашкинаМ. И.ChashkinaM. I.

Чашкина Мария Игоревна — ассистент кафедры кардиологии, функциональной и ультразвуковой диагностики ИКМ им. Н.В. Склифосовского.

Москва.

Maria I. Chashkina - Assistant Professor of the department of cardiology, functional and ultrasound diagnostics N.V. Sklifosovsky Clinical  Medicine Institution.

Moscow.

vebmar@mail.ruhttps://orcid.org/0000-0002-3279-7566СалпагароваЗ. К.SalpagarovaZ. K.

Салпагарова Зухра Казбековна — кандидат медицинских наук, доцент кафедры кардиологии, функциональной и ультразвуковой диагностики ИКМ им. Н.В. Склифосовского.

Москва.

Zukhra K. Salpagarova - Associate  Professor of the department of cardiology, functional and ultrasound diagnostics N.V. Sklifosovsky Clinical  Medicine Institution.

Moscow.

zuxrisha@mail.ruПервый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет); ГКБ № 1 им. Н.И. Пирогова Департамента здравоохранения города МосквыI.M. Sechenov First Moscow State Medical University; City Clinical Hospital № 1Первый МГМУ им. И.М. Сеченова Минздрава России (Сеченовский Университет)I.M. Sechenov First Moscow State Medical University20211007202120529742974Copyright © Серова М.В., Андреев Д.А., Чашкина М.И., Салпагарова З.К., 20212021Серова М.В., Андреев Д.А., Чашкина М.И., Салпагарова З.К.Serova M.V., Andreev D.A., Chashkina M.I., Salpagarova Z.K.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://cardiovascular.elpub.ru/jour/article/view/2974

Катетерная аблация (КА) фибрилляции и трепетания предсердий сопряжена с высоким риском как перипроцедуральных тромбоэмболических событий, так и кровотечений. Достаточная антикоагуляция является обязательной для снижения риска развития осложнений. Цель обзора — анализ современных подходов к антикоагулянтной терапии при КА фибрилляции и трепетания предсердий, а также предоставление практической информации на основании сравнения действующих рекомендаций и существующей доказательной базы. Проведен поиск литературных источников, посвященных антикоагулянтной терапии при КА, в базах данных PubMed, Scopus, Web of Science. Представлены результаты ключевых рандомизированных исследований и метаанализов, приведено сравнение текущих российских и международных рекомендаций. Обсуждены нерешенные вопросы, требующие проведения дальнейших исследований.

Catheter ablation (CA) of atrial fibrillation and flutter is associated with a high risk of both perioperative thromboembolic events and bleeding. Adequate anticoagulation is imperative to reduce the risk of complications. The aim of this review was to analyze modern approaches to anticoagulant therapy for CA of atrial fibrillation and flutter, as well as provide practical information based on a comparison of current guidelines and evidence base. The search for literature sources on anticoagulant therapy in CA was carried out in the PubMed, Scopus, Web of Science databases. The results of key randomized trials and meta-analyzes are presented, and a comparison of current Russian and international guidelines is given. Unresolved issues requiring further research are discussed.

фибрилляция предсердийкатетерная аблациятрепетание предсердийантикоагулянтная терапияпериоперационное ведениеatrial fibrillationcatheter ablationatrial flutteranticoagulant therapyperioperative managementСтатья подготовлена при финансовой поддержке компании Пфайзер. В статье выражена позиция авторов, которая может отличаться от позиции компании Пфайзер.This article was financially supported by Pfizer. The article expresses the authors' position, which may differ from Pfizer.ReferencesАракелян М. Г., Бокерия Л. А., Васильева Е. Ю. и др. Фибрилляция и трепетание предсердий. Клинические рекомендации 2020. Российский кардиологический журнал. 2021;26(7):4594. doi:10.15829/1560-4071-2021-4594.Arakelyan MG, Bokeria LA, Vasilyeva EYu, et al. 2020 Clinical practice guidelines for Atrial fibrillation and atrial flutter. 2020. Russian Journal of Cardiology. 2021;26(7):4594. (In Russ.)Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373-498. doi:10.1093/eurheartj/ehaa612.Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2020;42:373-498. doi:10.1093/eurheartj/ehaa612.Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019;321:1059-68. doi:10.1001/jama.2019.0335.Blomstrom-Lundqvist C, Gizurarson S, Schwieler J, et al. Effect of catheter ablation vs antiarrhythmic medication on quality of life in patients with atrial in patients with atrial fibrillation: the CAPTAF randomized clinical trial. JAMA. 2019;321:1059-68. doi:10.1001/jama.2019.0335.Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1275-85. doi:10.1001/jama.2019.0692.Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019; 321:1275-85. doi:10.1001/jama.2019.0692.Kuck KH, Lebedev D, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace. 2021;23:362-9. doi:10.1093/europace/euaa298.Kuck KH, Lebedev D, Mikhaylov EN, et al. Catheter ablation or medical therapy to delay progression of atrial fibrillation: the randomized controlled atrial fibrillation progression trial (ATTEST). Europace. 2021;23:362-9. doi:10.1093/europace/euaa298.Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial of atrial fibrillation. N Engl J Med. 2021;384:305-15. doi:10.1056/NEJMoa2029980.Andrade JG, Wells GA, Deyell MW, et al. Cryoablation or drug therapy for initial of atrial fibrillation. N Engl J Med. 2021;384:305-15. doi:10.1056/NEJMoa2029980.Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316-24. doi:10.1056/NEJMoa2029554.Wazni OM, Dandamudi G, Sood N, et al. Cryoballoon ablation as initial therapy for atrial fibrillation. N Engl J Med. 2021;384:316-24. doi:10.1056/NEJMoa2029554.Packer DL, Mark DB, Robb RA, et al. CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-74. doi:10.1001/jama.2019.0693.Packer DL, Mark DB, Robb RA, et al. CABANA Investigators. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019;321:1261-74. doi:10.1001/jama.2019.0693.Packer DL, Monahan KH, Al-Khalidi HR, et al. Ablation of Atrial Fibrillation in Heart Failure Patients: Additional outcomes of the CABANA Trial. Heart Rhythm. 2019;16(Suppl):S35. doi:10.1161/CIRCULATIONAHA.120.050991.Packer DL, Monahan KH, Al-Khalidi HR, et al. Ablation of Atrial Fibrillation in Heart Failure Patients: Additional outcomes of the CABANA Trial. Heart Rhythm. 2019;16(Suppl):S35. doi:10.1161/CIRCULATIONAHA.120.050991.Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020;17:1057-65. doi:10.1016/j.hrthm.2020.02.030.Noseworthy PA, Van Houten HK, Gersh BJ, et al. Generalizability of the CASTLE-AF trial: catheter ablation for patients with atrial fibrillation and heart failure in routine practice. Heart Rhythm. 2020;17:1057-65. doi:10.1016/j.hrthm.2020.02.030.Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1-160. doi:10.1093/europace/eux274.Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/ APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018;20(1):e1-160. doi:10.1093/europace/eux274.Martin A-C, Godier A, Narayanan K, et al. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation. Understanding the Gaps in Evidence. Circulation. 2018;138:627-33. doi:10.1161/CIRCULATIONAHA.117.033326.Martin A-C, Godier A, Narayanan K, et al. Management of Intraprocedural Anticoagulation in Patients on Non-Vitamin K Antagonist Oral Anticoagulants Undergoing Catheter Ablation for Atrial Fibrillation. Understanding the Gaps in Evidence. Circulation. 2018;138:627-33. doi:10.1161/CIRCULATIONAHA.117.033326.Goldi T, Krisai P, Knecht S, et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5:1406-14. doi:10.1016/j.jacep.2019.09.003.Goldi T, Krisai P, Knecht S, et al. Prevalence and Management of Atrial Thrombi in Patients With Atrial Fibrillation Before Pulmonary Vein Isolation. JACC Clin Electrophysiol. 2019;5:1406-14. doi:10.1016/j.jacep.2019.09.003.Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. EP Europace. 2021:euab065. doi:10.1093/europace/euab065.Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management. Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation. 2014;129:2638-44. doi:10.1161/CIRCULATIONAHA.113.006426.Di Biase L, Burkhardt JD, Santangeli P, et al. Periprocedural Stroke and Bleeding Complications in Patients Undergoing Catheter Ablation of Atrial Fibrillation With Different Anticoagulation Management. Results From the Role of Coumadin in Preventing Thromboembolism in Atrial Fibrillation (AF) Patients Undergoing Catheter Ablation (COMPARE) Randomized Trial. Circulation. 2014;129:2638-44. doi:10.1161/CIRCULATIONAHA.113.006426.Konduru SV, Cheema AA, Jones РИ, et al. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol. 2012;35:277-84. doi:10.1007/s10840-012-9719-9.Konduru SV, Cheema AA, Jones РИ, et al. Differences in intraprocedural ACTs with standardized heparin dosing during catheter ablation for atrial fibrillation in patients treated with dabigatran vs. patients on uninterrupted warfarin. J Interv Card Electrophysiol. 2012;35:277-84. doi:10.1007/s10840-012-9719-9.Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805-11. doi:10.1093/eurheartj/ehv177.Cappato R, Marchlinski FE, Hohnloser SH, et al. Uninterrupted rivaroxaban vs. uninterrupted vitamin K antagonists for catheter ablation in non-valvular atrial fibrillation. Eur Heart J. 2015;36:1805-11. doi:10.1093/eurheartj/ehv177.Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376:1627-36. doi:10.1056/NEJMoa1701005.Calkins H, Willems S, Gerstenfeld EP, et al. Uninterrupted Dabigatran versus Warfarin for Ablation in Atrial Fibrillation. N Engl J Med. 2017;376:1627-36. doi:10.1056/NEJMoa1701005.Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39:2942-55. doi:10.1093/eurheartj/ehy176.Kirchhof P, Haeusler KG, Blank B, et al. Apixaban in patients at risk of stroke undergoing atrial fibrillation ablation. Eur Heart J. 2018;39:2942-55. doi:10.1093/eurheartj/ehy176.Hohnloser SH, Camm J, Cappato R. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40:3013-21. doi:10.1093/eurheartj/ehz190.Hohnloser SH, Camm J, Cappato R. Uninterrupted edoxaban vs. vitamin K antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial. Eur Heart J. 2019;40:3013-21. doi:10.1093/eurheartj/ehz190.Zhao Yu, Yang Yu, Tang X, et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017;267-82. doi:10.1007/s10840-016-0221-7.Zhao Yu, Yang Yu, Tang X, et al. New oral anticoagulants compared to warfarin for perioperative anticoagulation in patients undergoing atrial fibrillation catheter ablation: a meta-analysis of continuous or interrupted new oral anticoagulants during ablation compared to interrupted or continuous warfarin. J Interv Card Electrophysiol. 2017;267-82. doi:10.1007/s10840-016-0221-7.Mao Y-J, Wang H, Huang P-F. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis. Pacing Clin Electrophysiol. 2020;43(10):1104-14. doi:10.1111/pace.14040.Mao Y-J, Wang H, Huang P-F. Peri-procedural novel oral anticoagulants dosing strategy during atrial fibrillation ablation: A meta-analysis. Pacing Clin Electrophysiol. 2020;43(10):1104-14. doi:10.1111/pace.14040.Cardoso R, Knijnik L, Bhonsale A, et al. An updated metaanalysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018;15:107-15. doi:10.1016/j.hrthm.2017.09.011.Cardoso R, Knijnik L, Bhonsale A, et al. An updated metaanalysis of novel oral anticoagulants versus vitamin K antagonists for uninterrupted anticoagulation in atrial fibrillation catheter ablation. Heart Rhythm. 2018;15:107-15. doi:10.1016/j.hrthm.2017.09.011.Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility And Safety of uninterrupted peri-procedural Apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results From a Multicenter Study. Heart Rhythm. 2015;12(6):1162-8. doi:10.1016/j.hrthm.2015.02.028.Di Biase L, Lakkireddy D, Trivedi C, et al. Feasibility And Safety of uninterrupted peri-procedural Apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results From a Multicenter Study. Heart Rhythm. 2015;12(6):1162-8. doi:10.1016/j.hrthm.2015.02.028.Bejinariu AG, Makimoto S, Wakili R, et al. One-year course of periprocedural anticoagulation in atrial fibrillation ablation: results of a German nationwide survey. Cardiology. 2020;145(10):676-81. doi:10.1159/000509399.Bejinariu AG, Makimoto S, Wakili R, et al. One-year course of periprocedural anticoagulation in atrial fibrillation ablation: results of a German nationwide survey. Cardiology. 2020;145(10):676-81. doi:10.1159/000509399.Reynolds MR, Allison JS, Natale A, et al. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation. The AEIOU Trial. JACC Clin Electrophysiol. 2018;4(5):580-8. doi:10.1016/j.jacep.2017.11.005.Reynolds MR, Allison JS, Natale A, et al. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation. The AEIOU Trial. JACC Clin Electrophysiol. 2018;4(5):580-8. doi:10.1016/j.jacep.2017.11.005.Medi C, Evered L, Silbert B, et al. Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation. J Am Coll Cardiol. 2013;62:531-9. doi:10.1016/j.jacc.2013.03.073.Medi C, Evered L, Silbert B, et al. Subtle Post-Procedural Cognitive Dysfunction After Atrial Fibrillation Ablation. J Am Coll Cardiol. 2013;62:531-9. doi:10.1016/j.jacc.2013.03.073.Schwarz N, Kuniss M, Nedelmann M, et al. Neuropsychological decline after catheter ablation of atrial fibrillation. Heart Rhythm. 2010;7:1761-7. doi:10.1016/j.hrthm.2010.07.035.Schwarz N, Kuniss M, Nedelmann M, et al. Neuropsychological decline after catheter ablation of atrial fibrillation. Heart Rhythm. 2010;7:1761-7. doi:10.1016/j.hrthm.2010.07.035.Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm. 2014;11(5):791-8. doi:10.1016/j.hrthm.2014.03.003.Di Biase L, Gaita F, Toso E, et al. Does periprocedural anticoagulation management of atrial fibrillation affect the prevalence of silent thromboembolic lesion detected by diffusion cerebral magnetic resonance imaging in patients undergoing radiofrequency atrial fibrillation ablation with open irrigated catheters? Results from a prospective multicenter study. Heart Rhythm. 2014;11(5):791-8. doi:10.1016/j.hrthm.2014.03.003.

The authors declare that there are no conflicts of interest present.